title: Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.
abstract: Pituitary adenomas (PA) represent in the majority of cases, benign tumors whose treatment currently associate surgery, medical therapies and radiotherapy in a multidisciplinary approach. While trans-sphenoidal surgery remains, except for prolactin-secreting adenomas, the first-line treatment of PA, it can considerably be hampered by the existence of an invasive and/or aggressive tumor for which medical therapies are often requested. In this review, we extensively discuss, both at molecular and clinical levels, the medical therapies currently used and in development in the different phenotypes of pituitary adenomas.
authors.affiliation: Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands; CRN2M, UMR 7286 CNRS, Aix-Marseille University, 13344 Marseille cedex 15, France; Department of Endocrinology, University Hospital of Nancy Brabois, 54500 Vandœuvre-Les-Nancy, France. Electronic address: t.cuny@chu-nancy.fr.
authors.forename: Thomas
authors.initials: T
authors.lastname: Cuny
authors.affiliation: CRN2M, UMR 7286 CNRS, Aix-Marseille University, 13344 Marseille cedex 15, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Barlier
authors.affiliation: Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: Richard
authors.initials: R
authors.lastname: Feelders
authors.affiliation: Department of Endocrinology, University Hospital of Nancy Brabois, 54500 Vandœuvre-Les-Nancy, France.
authors.forename: Georges
authors.initials: G
authors.lastname: Weryha
authors.affiliation: Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: Leo J
authors.initials: LJ
authors.lastname: Hofland
authors.affiliation: Endocrinology, Department of Internal Medicine & Medical Specialities (DiMI), Center of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy; Endocrinology, IRCCS AOU San Martino-IST, Genova, Italy.
authors.forename: Diego
authors.initials: D
authors.lastname: Ferone
authors.affiliation: Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands; Endocrinology, Department of Internal Medicine & Medical Specialities (DiMI), Center of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy; Endocrinology, IRCCS AOU San Martino-IST, Genova, Italy.
authors.forename: Federico
authors.initials: F
authors.lastname: Gatto
mesh_terms: D049913:ACTH-Secreting Pituitary Adenoma / Q000188:drug therapy; D000172:Acromegaly / Q000188:drug therapy; D000236:Adenoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D018491:Dopamine Agonists / Q000627:therapeutic use; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000188:drug therapy; D006801:Humans; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015175:Prolactinoma / Q000178:diet therapy; D013004:Somatostatin / Q000031:analogs & derivatives; D013972:Thyrotropin / Q000378:metabolism
chemical_list: D018491:Dopamine Agonists; D013004:Somatostatin; D013972:Thyrotropin
keywords: Acromegaly; Acromégalie; Adénomes hypophysaires; Agonistes dopaminergiques; Analogues de la somatostatine; Cushing's disease; Dopamin agonist; Maladie de Cushing; Pituitary adenomas; Somatostatin analog